Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 


argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis …


ABLYNX INITIATES PHASE IIb STUDY OF INHALED ANTI-RSV NANOBODY

ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections. The drug was found to be safe and well tolerated in …

POPULAR TAGS

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle

Written by ALB on in the category news with the tags .


14 Nov 2018

-

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mithra’s novel combined oral contraceptive (COC), containing 15 mg Estetrol (E4)/ 3 mg drospirenone (DRSP). Top line data remain on track to be reported in Q1 2019.

The E4 Freedom Estelle® Phase III program consists of two open-label, single arm studies. In August Mithra reported positive top-line results of the study conducted in Europe and Russia. The study successfully met its primary efficacy endpoint, indicating excellent contraceptive efficacy, with a Pearl Index (PI) of 0.475 per 100 women, exceeding efficacy goals. Key secondary endpoints were also achieved, including outstanding bleeding profile, cycle control, quality of life and safety and tolerability with no unexpected safety events. In both EU/Russian and US/Canadian studies 3.725 women were recruited.

The two pivotal studies have exceeded the minimum total required cycles by 50% which further reinforces Mithra’s confidence to meet major regulatory requirement from agencies.

The US/Canadian Pearl Index (PI) early results show that Estelle® PI would be in the range of one of the bestselling COC’s in the USA ( Lo-loestrin®[1] EUR 758 million sales with CAGR 8%[2]).

The EU/Russian results and early US/Canadian trial together with the previous positive results[3] from the Phase II study showing an excellent hemostatic safety profile suggest Estelle® has the potential to become a true next generation COC product addressing a clear unmet needs in women’s health.

Valerie Gordenne, CSO Mithra Women’s Health, commented: “The E4 Freedom trials are our most advanced clinical studies for our lead candidate Estelle®. The completion of the US/Canadian pivotal trial represents a great achievement for the company and a key development milestone in preparation of future regulatory submission. The contraceptive’s efficacy; safety, hemostatic, and metabolic profile for Estelle® is very promising and we remain confident with future regulatory progress. We look forward to reporting additional phase III top-line results in Q1 2019”

François Fornieri, CEO of Mithra Women’s Health commented : “We are proud to reach this major development milestone for the company which brings Estelle® a step closer to market. Previous top-line results from the EU/Russia Phase III study have demonstrated that Estelle has the potential to be a novel, ‘next generation’ oral contraceptive option for women. Estelle® is a highly attractive candidate with promising commercial prospects, particularly in the US, where the oral contraceptive market is twice the size of the European market. ”

About the E4 Freedom Estelle® Phase III program
The E4 Freedom Phase III program consists of two open-label, single arm studies. The European/Russian Phase III Estelle® study has enrolled 1,577 subjects aged 18-50 years of whom 1,350 subjects are aged 18-35 years. The study is taking place in 69 centers across Europe and Russia. The Phase III Estelle® study design in the US & Canada has enrolled 2,148 subjects aged 16-50 years of whom 1,940 subjects are aged 16-35 years. The study is taking place in 77 centers across the US and Canada. Estelle® is Mithra’s combined oral contraceptive (COC) candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).

The objectives of both studies are to evaluate the contraceptive’s efficacy, cycle control, and the general safety and acceptability of the 15 mg E4 (Estetrol) and 3 mg DRSP combination oral contraceptive pill in healthy women, and involves subject participation for a period of minimum 12 months (13 cycles, 1 cycle = 28 days).

The primary outcome is contraceptive efficacy measured by the number of pregnancies per 100 women per 12 months of exposure (Pearl Index; PI) in the primary population. In Europe/Russia this is in subjects aged 18-35 years old and in the US/Canada in subjects aged 16 to 35 years old.
Secondary outcomes include the method failure PI in the primary population as well as the PI within the overall study population. Also, cycle control and bleeding profile, safety and tolerability, and general wellbeing of the subjects (measured by two questionnaires) are analyzed. A pharmacokinetic (PK) substudy, in the US/Canada , will assess the effect of various individual characteristics/covariates (such as race and BMI) on the PK profile of 15 mg E4/3 mg DRSP.

About Mithra
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on fertility, contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle® and next-generation hormone therapy Donesta® - are built on Mithra’s unique native estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Read more about: .

RELATED ARTICLES
Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 


argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis …


ABLYNX INITIATES PHASE IIb STUDY OF INHALED ANTI-RSV NANOBODY

ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections. The drug was found to be safe and well tolerated in …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven XpandInnovation GSK V-Bio Ventures Itera Life Science Janssen UGent Turnstone Biowin Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.